BACKGROUND: Selective breeding of rats over generations and induction of alcohol dependence via chronic vapor inhalation both enhance alcohol consumption in animal models. The purpose of this study was to determine whether dependence-induced increases in alcohol consumption by P rats is sensitive to naltrexone, a general opioid receptor antagonist (but with highest affinity at the mu-opioid receptor at low doses), and the recently characterized small molecule CRF(1)-receptor antagonist MPZP (N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-amine). METHODS: P rats (n = 20) were trained to respond for alcohol and water in a 2-lever operant situation during daily 30-minute sessions. P rats were then matched for alcohol intake and exposed to chronic intermittent alcohol vapor (n = 10) or ambient air (n = 10) for approximately 10 weeks. All rats were then administered MPZP and naltrexone in 2 separate and consecutive Latin-square designs. RESULTS: MPZP attenuated dependence-induced increases in alcohol intake by P rats while having no effect on alcohol consumption by nondependent controls. Conversely, operant alcohol responding was reduced similarly in dependent and nondependent P rats by naltrexone. CONCLUSIONS: These results confirm a role for brain CRF(1)-receptor systems in dependence-induced changes in the reinforcing properties of alcohol, and CRF(1)-receptor blockade appears to suppress dependence-induced drinking at lower doses in P rats relative to other rat lines. Therefore, brain CRF(1)-receptor systems are important in the regulation of dependence-induced alcohol consumption, whereas brain opioid systems are important in the regulation of basal alcohol consumption by rats.
BACKGROUND: Selective breeding of rats over generations and induction of alcohol dependence via chronic vapor inhalation both enhance alcohol consumption in animal models. The purpose of this study was to determine whether dependence-induced increases in alcohol consumption by P rats is sensitive to naltrexone, a general opioid receptor antagonist (but with highest affinity at the mu-opioid receptor at low doses), and the recently characterized small molecule CRF(1)-receptor antagonist MPZP (N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-amine). METHODS: P rats (n = 20) were trained to respond for alcohol and water in a 2-lever operant situation during daily 30-minute sessions. P rats were then matched for alcohol intake and exposed to chronic intermittent alcohol vapor (n = 10) or ambient air (n = 10) for approximately 10 weeks. All rats were then administered MPZP and naltrexone in 2 separate and consecutive Latin-square designs. RESULTS:MPZP attenuated dependence-induced increases in alcohol intake by P rats while having no effect on alcohol consumption by nondependent controls. Conversely, operant alcohol responding was reduced similarly in dependent and nondependent P rats by naltrexone. CONCLUSIONS: These results confirm a role for brain CRF(1)-receptor systems in dependence-induced changes in the reinforcing properties of alcohol, and CRF(1)-receptor blockade appears to suppress dependence-induced drinking at lower doses in P rats relative to other rat lines. Therefore, brain CRF(1)-receptor systems are important in the regulation of dependence-induced alcohol consumption, whereas brain opioid systems are important in the regulation of basal alcohol consumption by rats.
Authors: Kathleen Chu; George F Koob; Maury Cole; Eric P Zorrilla; Amanda J Roberts Journal: Pharmacol Biochem Behav Date: 2007-04-03 Impact factor: 3.533
Authors: A C Hansson; A Cippitelli; W H Sommer; A Fedeli; K Björk; L Soverchia; A Terasmaa; M Massi; M Heilig; R Ciccocioppo Journal: Proc Natl Acad Sci U S A Date: 2006-10-02 Impact factor: 11.205
Authors: Valentina Sabino; Pietro Cottone; George F Koob; Luca Steardo; Mei J Lee; Kenner C Rice; Eric P Zorrilla Journal: Psychopharmacology (Berl) Date: 2006-10-18 Impact factor: 4.530
Authors: Zachary A Rodd; Richard L Bell; Helen J K Sable; James M Murphy; William J McBride Journal: Pharmacol Biochem Behav Date: 2004-11 Impact factor: 3.533
Authors: Donald R Gehlert; Andrea Cippitelli; Annika Thorsell; Anh Dzung Lê; Philip A Hipskind; Chafiq Hamdouchi; Jianliang Lu; Erik J Hembre; Jeffrey Cramer; Min Song; David McKinzie; Michelle Morin; Roberto Ciccocioppo; Markus Heilig Journal: J Neurosci Date: 2007-03-07 Impact factor: 6.167
Authors: Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng Journal: Pharmacol Biochem Behav Date: 2012-07-25 Impact factor: 3.533